1 / 6

GSK Perspective on Universal Vaccination Against Influenza

GSK Perspective on Universal Vaccination Against Influenza. Varsha K. Jain, MD Director, Clinical R&D and Medical Affairs, Vaccine for Virus Diseases, North America GlaxoSmithKline. GSK’s Commitment to Influenza Vaccines.

travis-bright
Télécharger la présentation

GSK Perspective on Universal Vaccination Against Influenza

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GSK Perspective on Universal Vaccination Against Influenza Varsha K. Jain, MD Director, Clinical R&D and Medical Affairs, Vaccine for Virus Diseases, North America GlaxoSmithKline

  2. GSK’s Commitment to Influenza Vaccines • Committed to be part of the long term solution of the country’s influenza public health concern • Responded to 2004/5 Influenza vaccine shortage, worked with FDA and CDC • Pursued FLUARIX licensure for adults in time for the 2005/6 season.

  3. GSK’s Commitment to Influenza Vaccines (Cont) • GSK is an advocate of childhood vaccination • GSK recognizes universal recommendations are the most successful national vaccination policies • Especially for children • GSK is pursuing pediatric indication for FLUARIX

  4. GSK’s Commitment for Influenza Prevention • Expanded manufacturing in Dresden, Germany • double influenza vaccine production capacity by 2008 • Acquired manufacturing facility in US (Marietta, PA) • cell culture based inter-pandemic and pandemic vaccines • Proposal to acquire ID Biomedical • manufacturing facilities in Canada and US • Developing improved influenza vaccines • using novel adjuvant

  5. Supply/Demand and Infrastructure • Supply should meet the demand • Demand will increase if influenza vaccination is universally recommended • Partnership to avoid over/under supply • Build infrastructure for yearly influenza vaccination to children and adults • same infrastructure can help pandemic preparation

  6. Conclusion • GSK supports universal vaccination against Influenza • GSK is taking steps to expand and diversify influenza vaccine supply • Essential to see a multiyear plan for universal vaccination • GSK will respond to that plan by further building its capacity to supply

More Related